Strategies at the interface of drug discovery and development: Early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates

Journal of Medicinal Chemistry

Volumn 53, Issue 16, 2010, Pages 5897-5905

  Palucki, Michael ^a   Higgins, John D ^a   Kwong, Elizabeth ^a   Templeton, Allen C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBOMER; DIETHYLENE GLYCOL MONOETHYL ETHER; DIMETHYL SULFOXIDE; DRUG DERIVATIVE; EXCIPIENT; NANOPARTICLE; POLYMER; POLYSORBATE; SURFACTANT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE TRANSITION; REVIEW; SOLID STATE; STRUCTURE ACTIVITY RELATION; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOLOGY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; TOXICITY TESTS;

EID: 77955915185     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1002638     Document Type: Review

References (40)

1. Lipinski, C. A.; Lombardo, R.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug. Delivery Rev. 1997, 23, 3-25
2. Di, L.; Kerns, E. H. Profiling drug-like properties in discovery research Curr. Opin. Chem. Biol. 2003, 7, 402-408
3. van de Waterbeemd, H.; Smith, D. A.; Beaumont, K; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics J. Med. Chem. 2001, 44, 1313-1333
4. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods; Academic Press: London, 2008.
5. Higgins, J. Perspectives on preformulation programs at the discovery-development interface Am. Pharm. Rev. 2009, 12, 42-46
6. Mass, J.; Kamm, W.; Hauck, G. An Integrated early formulation strategy-from hit evaluation to preclinical candidate profiling Eur. J. Pharm. Biopham. 2007, 66, 1-10
7. For an early report on a multidisciplinary approach to compound optimization, see the following: Caldwell, G. W.; Ritchie, D. M.; Masucci, J. A.; Hageman, W.; Yan, Z. The new pre-clinical paradigm: compound optimization in early and late phase drug discovery Curr. Top. Med Chem. 2001, 1, 353-366
8. Gould, P. L. Salt selection for basic drugs Int. J. Pharm. 1986, 33, 201-217
9. For a report on the use of simulated gastrointestinal fluids for predicting oral drug absorption, see the following: Horter, D.; Dressman, J. Influence of physicochemical properties of drugs in the gastrointestinal tract Adv. Drug Delivery Rev. 1997, 25, 3-14
10. For a recent review on this topic, with representative case studies, see the following: Li, P.; Zhao, L. Developing early formulations: practice and principle Int. J. Pharm. 2007, 341, 1-19
11. Desrosiers, P. J. The potential for perform: an integrated approach to preformulation allows researchers to complete this crucial step earlier in drug development process Modern Drug Discovery 2004, January, 40-43
12. Ku, M. S. Salt and polymorph selection strategy based on the biopharmaceutical classification system for early pharmaceutical development Am. Pharm. Rev. 2010, 22-30
13. Morris, K. R.; Fakes, M. G.; Thakur, A. B.; Newman, A. W.; Singh, A. K.; Venit, J. J.; Spagnuolo, C. J.; Serajuddin, A. T. M. An integrated approach to the selection of optimal salt form for a new drug candidate Int. J. Pharm. 1994, 105, 209-217
14. Saal, C. Pharmaceutical salts optimization of solubility or even more? Am. Pharm. Rev. 2010, 18-22
15. For an excellent approach encompassing developability assessment of potential drug candidates, see the following: Saxena, V.; Panicucci, R.; Joshi, Y.; Garad, S. Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates J. Pharm. Sci. 2009, 98, 1962-1979
16. The choice of rodent and nonrodent species is driven by individual program specifics and is based on a number of factors such as which is the best model for human PK prediction, safety driven concerns, metabolism issues, etc.
17. Utilization of prodrugs has emerged as a viable means to address poor solubility and exposure. For reference, see the following: Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs J. Med. Chem. 2004, 47, 2393-2404
18. Oh, D.-M.; Sinko, P. J.; Amidon, G. L. Predicting Oral Drug Absorption in Humans: A Macroscopic Mass Balance Approach for Passive and Carrier-Mediated Compounds. In Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis; D'Argenio, D. Z., Ed.; Plenum Press: New York, 1991; pp 3 - 11.
19. Oh, D.-M.; Curl, R. L.; Amidon, G. L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model Pharm. Res. 1993, 19, 264-270
20. For a seminal paper on BCS, see the following: Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413
21. Rosen, H.; Abribat, T. The rise and rise of drug delivery Nat. Rev. Drug Discovery 2005, 4, 381-385
22. Chaubal, M. V. Application of formulation technologies in lead candidate selection and optimization Drug Discovery Today 2004, 9, 603-609
23. See for example Mass, J.; Kamm, W.; Hauck, G. An integrated early formulation strategy-from hit evaluation to preclinical candidate profiling Eur. J. Pharm. Biopharm. 2007, 66, 1-10
24. Merisko-Liversidge, E.; Liversidge, G.; Cooper, E. Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 2003, 18, 113-120
25. Timpe, C. Drug solubilization strategies: applying nanoparticle formulation and solid dispersion approaches to drug development Am. Pharm. Rev. 2010, 12-21
26. Muller, R. H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: rational for development and what we can expect for the future Adv. Drug Delivery 2001, 47, 3-19
27. Watts, A. B.; Williams, R. O., III. Formulation and Production Strategies for Enhancing Bioavailability of Poorly Absorbed Drugs. In Preclinical Drug Development, 2 nd ed.; Rogge, M. C.; Taft, D. R., Eds.; Drugs and the Pharmaceutical Sciences, Vol. 187; Informa Healthcare USA: New York, 2010; pp 161 - 195.
28. Yu, L.; Bridgers, A.; Polli, J.; Vickers, A.; Long, S.; Roy, A.; Winnike, R.; Coffin, M. Pharm. Res. 1999, 16, 1812-1817
29. Porter, C. J. H.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6, 231-248
30. For an example of the use of a self-microemulsifying drug delivery systems (SMEDDS) for enhancing exposure, see the following: Kommuru, T. R.; Gurley, B.; Khan, M. A.; Reddy, I. K. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment Int. J. Pharm. 2001, 212, 233-246
31. Mass, J.; Kamm, W.; Hauck, G. An integrated early formulation strategy-from hit evaluation to preclinical candidate profiling Eur. J. Pharm. Biopharm. 2007, 66, 1-10
32. For a report on formulations for cell permeability enhancement, see the following: Paranjpe, P.; Sinko, P. Overcoming paracellular tissue barriers for drug delivery Pharm. News 2002, 9 (6) 381-395
33. Hancock, B.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 1997, 86 (1) 1-12
34. Vervaet, C.; Baert, L.; Remon, J. P. Extrusion-speronisation: a literature review Int. J. Pharm. 1995, 116, 131-146
35. Jung, J.-J.; Yoo, S. D.; Lee, S.-H.; Kim, K.-H.; Yoon, D.-S.; Lee, K.-H. Enhanced solubility and dissolution rate of itraconizole by a solid dispersion technique Int. J. Pharm. 1999, 187, 209-218
36. Strickley, G. Solubilizing excipients in oral and injectable formulations Pharm. Res. 2004, 21, 201-230
37. Pestel, S.; Martin, H.-J.; Maier, G.-M.; Guth, B. Effects of commonly used vehicles on gastrointestinal, renal and liver function in rats J. Pharmacol. Toxicol. Methods 2006, 54, 200-214
38. Gad, S. C.; Cassidy, C.; Aubert, N.; Spainhour, B.; Robbe, H. Nonclinical vehicle use in studies by multiple routes in multiple species Int. J. Toxicol. 2006, 25, 449-521
39. Neervannan, S. Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2006, 2 (5) 715-731
40. Svenson, S.; Tomolia, D. Dendrimers in biomedical applications- reflections on the field Adv. Drug Delivery 2005, 57, 2106-2129